GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (STU:8IM1) » Definitions » Total Current Liabilities

Implantica AG (STU:8IM1) Total Current Liabilities : €0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Implantica AG's total current liabilities for the quarter that ended in . 20 was €0.00

Implantica AG Total Current Liabilities Historical Data

The historical data trend for Implantica AG's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Total Current Liabilities Chart

Implantica AG Annual Data
Trend
Total Current Liabilities

Implantica AG Semi-Annual Data
Total Current Liabilities

Implantica AG Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Implantica AG's Total Current Liabilities for the fiscal year that ended in . 20 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=+
+Other Current Liabilities+Current Deferred Liabilities
=+
=0.00

Implantica AG's Total Current Liabilities for the quarter that ended in . 20 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=+
+Other Current Liabilities+Current Deferred Liabilities
=+
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Implantica AG Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Implantica AG's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Implantica AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (STU:8IM1) » Definitions » Total Current Liabilities
Comparable Companies
Traded in Other Exchanges
IMP A SDB:Sweden 8IM1:Germany
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Website
https://www.implantica.com
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines